PureTech Health (GB:PRTC) has released an update.
PureTech Health PLC successfully passed all resolutions at its Annual General Meeting on June 13, 2024, despite over 20% dissenting votes on executive remuneration and the re-election of a director. The company has since engaged with shareholders representing a majority of its share capital to discuss concerns and gain broad support for its revised Remuneration Policy. PureTech, a clinical-stage biotherapeutics company, continues to focus on advancing its pipeline of 29 therapeutics, with several in late-stage clinical development.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
